• Sales for the quarter up 23% to US$5.8 million (A$8.2 million)
• Last Twelve Months (LTM) global sales up 24% to ~US$22.0 million (A$33.2 million)
• EBITDA loss reduced to US$75,000 (A$107,000) from US$482,000 (A$773,000) in the prior period

Nova Eye Medical Limited, a medical technology company focused on advanced ophthalmic treatment technologies and devices, has reported its quarterly activities and cashflow report for the three months ended 31 March 2026. The company achieved sales of US$5.8 million (A$8.2 million) for the quarter, representing a 23% increase on the prior comparative period. This growth was underpinned by sustained momentum in the United States, where sales grew 28% to US$4.5 million, as well as the first sales of the iTrack™ Advance product into China. Last Twelve Months (LTM) global sales reached ~US$22.0 million (A$33.2 million), up 24% year-on-year. The company reported a material improvement in EBITDA, with a loss of US$75,000 (A$107,000) for the quarter, compared to a loss of US$482,000 (A$773,000) in the prior comparative period. This was driven by higher gross margins and an improved operating expenditure-to-sales ratio. The group's cash outflow from operations for the quarter was A$1.2 million, which was impacted by advance payments for marketing and sales activities, as well as the deterioration of the US dollar against the Australian dollar. The company continues to manage its working capital to support growth, with cash on hand of A$1.2 million at the end of the quarter and A$2.14 million of unused debt facilities. Nova Eye Medical has updated its FY26 sales guidance (excluding China) to be between US$21 million and US$22 million, and reaffirmed its expectation of breakeven or a small positive EBITDA in the second half of FY26.

Sales revenue (excl. China) for FY26 expected to be between US$21 million and US$22 million (A$30.9 million to A$32.4 million), implying a minimum 21% growth and mid guidance growth of 30%. Targeting breakeven EBITDA in H2FY26.

The company expects continued improvement in operating results, including positive EBITDA for the four months to 31 March 2026 and breakeven to small positive EBITDA in H2FY26. Ongoing improvement in operating cash flow is also anticipated.